多发性骨髓瘤治疗药物新适应症获批 耐药性推动肿瘤药研发新需求

第一财经
25 Jan

1月24日,赛诺菲抗CD38单抗艾沙妥昔单抗注射液(商品名:赛可益)的一项新适应症获得国家药品监督管理局(NMPA)批准,这也是该药物本月获批的第二项适应症,用于与硼替佐米、来那度胺和地塞米松(VRd)联合,治疗不适合自体干细胞移植(ASCT)的新诊断的多发性骨髓瘤(NDMM)成人患者。  多发性骨髓瘤是第二大最常见的恶性血液肿瘤,高发于老年群体,且发病率持续上升,逐渐成为老年人的“健康杀手”。...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10